USD 0.99
(13.45%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 55.45 Million USD | -34.44% |
2022 | 84.57 Million USD | 7.63% |
2021 | 78.57 Million USD | -1.5% |
2020 | 79.77 Million USD | 80.26% |
2019 | 44.25 Million USD | 101.68% |
2018 | 21.94 Million USD | -10.21% |
2017 | 24.44 Million USD | -2.13% |
2016 | 24.97 Million USD | 240.97% |
2015 | 7.32 Million USD | 17.35% |
2014 | 6.24 Million USD | -70.48% |
2013 | 21.13 Million USD | -32.78% |
2012 | 31.44 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 44.14 Million USD | -20.38% |
2024 Q2 | 47.4 Million USD | 7.36% |
2023 Q2 | 61.77 Million USD | -38.35% |
2023 Q1 | 100.21 Million USD | 18.48% |
2023 Q3 | 56.55 Million USD | -8.45% |
2023 FY | 55.45 Million USD | -34.44% |
2023 Q4 | 55.45 Million USD | -1.95% |
2022 Q1 | 72.63 Million USD | -7.56% |
2022 FY | 84.57 Million USD | 7.63% |
2022 Q4 | 84.57 Million USD | -11.05% |
2022 Q3 | 95.08 Million USD | 5.49% |
2022 Q2 | 90.13 Million USD | 24.09% |
2021 Q1 | 74.14 Million USD | -7.06% |
2021 Q3 | 72.26 Million USD | -18.63% |
2021 FY | 78.57 Million USD | -1.5% |
2021 Q4 | 78.57 Million USD | 8.73% |
2021 Q2 | 88.81 Million USD | 19.78% |
2020 Q4 | 79.77 Million USD | 193.37% |
2020 Q2 | 38.93 Million USD | 11.07% |
2020 Q3 | 27.19 Million USD | -30.15% |
2020 FY | 79.77 Million USD | 80.26% |
2020 Q1 | 35.05 Million USD | -20.8% |
2019 Q3 | 27.67 Million USD | -9.78% |
2019 FY | 44.25 Million USD | 101.68% |
2019 Q4 | 44.25 Million USD | 59.93% |
2019 Q2 | 30.67 Million USD | -9.08% |
2019 Q1 | 33.73 Million USD | 53.73% |
2018 Q4 | 21.94 Million USD | -7.68% |
2018 FY | 21.94 Million USD | -10.21% |
2018 Q1 | 28.64 Million USD | 17.2% |
2018 Q2 | 31.49 Million USD | 9.96% |
2018 Q3 | 23.77 Million USD | -24.53% |
2017 Q3 | 22.35 Million USD | 10.78% |
2017 Q4 | 24.44 Million USD | 9.33% |
2017 FY | 24.44 Million USD | -2.13% |
2017 Q1 | 23.12 Million USD | -7.41% |
2017 Q2 | 20.17 Million USD | -12.73% |
2016 FY | 24.97 Million USD | 240.97% |
2016 Q2 | 9.64 Million USD | 71.17% |
2016 Q1 | 5.63 Million USD | -23.03% |
2016 Q4 | 24.97 Million USD | -10.29% |
2016 Q3 | 27.83 Million USD | 188.49% |
2015 Q4 | 7.32 Million USD | 19.58% |
2015 Q2 | 7.9 Million USD | 6.56% |
2015 Q1 | 7.41 Million USD | 18.88% |
2015 FY | 7.32 Million USD | 17.35% |
2015 Q3 | 6.12 Million USD | -22.53% |
2014 Q1 | 33.4 Million USD | 58.02% |
2014 FY | 6.24 Million USD | -70.48% |
2014 Q4 | 6.24 Million USD | 7.2% |
2014 Q3 | 5.82 Million USD | -10.92% |
2014 Q2 | 6.53 Million USD | -80.43% |
2013 Q1 | - USD | 0.0% |
2013 Q4 | 21.13 Million USD | 0.0% |
2013 FY | 21.13 Million USD | -32.78% |
2012 FY | 31.44 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 94.15% |
Embecta Corp. | 2.03 Billion USD | 97.277% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 88.244% |
Dynavax Technologies Corporation | 375.02 Million USD | 85.214% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 91.609% |
Pacira BioSciences, Inc. | 704.25 Million USD | 92.126% |
PainReform Ltd. | 2.69 Million USD | -1960.572% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | 66.169% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -803.153% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -502.939% |
Cosmos Health Inc. | 30.25 Million USD | -83.29% |
Journey Medical Corporation | 56.49 Million USD | 1.857% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -803.153% |
Safety Shot Inc | 3.89 Million USD | -1324.701% |
Alpha Teknova, Inc. | 38.55 Million USD | -43.835% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | 59.487% |
Bright Green Corporation | 6.43 Million USD | -761.279% |
Procaps Group, S.A. | 462.06 Million USD | 88.0% |
Theratechnologies Inc. | 98.63 Million USD | 43.785% |
Harrow Health, Inc. | 241.75 Million USD | 77.063% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -533.28% |
Biofrontera Inc. | 23.13 Million USD | -139.639% |
DURECT Corporation | 30.4 Million USD | -82.365% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 88.625% |
Cronos Group Inc. | 43.73 Million USD | -26.783% |
OptiNose, Inc. | 194.33 Million USD | 71.467% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 93.216% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -14.46% |
RedHill Biopharma Ltd. | 20.97 Million USD | -164.323% |
Organogenesis Holdings Inc. | 181.36 Million USD | 69.426% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -1369.99% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -5.586% |
Radius Health, Inc. | 804.29 Million USD | 93.106% |
Universe Pharmaceuticals INC | 13.75 Million USD | -303.146% |
ProPhase Labs, Inc. | 42.54 Million USD | -30.336% |
Phibro Animal Health Corporation | 725.54 Million USD | 92.357% |
Procaps Group S.A. | 462.06 Million USD | 88.0% |
Alvotech | 1.88 Billion USD | 97.055% |
TherapeuticsMD, Inc. | 14.02 Million USD | -295.45% |
Viatris Inc. | 27.21 Billion USD | 99.796% |
Rockwell Medical, Inc. | 30.88 Million USD | -79.554% |
Aytu BioPharma, Inc. | 90.37 Million USD | 38.647% |
SIGA Technologies, Inc. | 57.97 Million USD | 4.359% |
Tilray Brands, Inc. | 892.11 Million USD | 93.784% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 74.773% |
Shineco, Inc. | 47.6 Million USD | -16.487% |
PetIQ, Inc. | 645.22 Million USD | 91.406% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -25160.578% |
Incannex Healthcare Limited | 5.83 Million USD | -851.115% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 94.561% |
Alimera Sciences, Inc. | 107.35 Million USD | 48.348% |
Silver Spike Investment Corp. | 3 Million USD | -1742.296% |
Assertio Holdings, Inc. | 148.41 Million USD | 62.639% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -2824.632% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -160.136% |
Clever Leaves Holdings Inc. | 7.02 Million USD | -689.212% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -553.08% |
Avadel Pharmaceuticals plc | 173.38 Million USD | 68.02% |
Hempacco Co., Inc. | 18.82 Million USD | -194.596% |
Talphera, Inc. | 6.29 Million USD | -781.558% |
Alvotech | 1.88 Billion USD | 97.055% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 67.874% |
Lantheus Holdings, Inc. | 835.25 Million USD | 93.361% |
Currenc Group, Inc. | 177.67 Million USD | 68.791% |
Kamada Ltd. | 109.96 Million USD | 49.576% |
Indivior PLC | 1.95 Billion USD | 97.158% |
Evoke Pharma, Inc. | 9.64 Million USD | -474.726% |
Flora Growth Corp. | 17.22 Million USD | -221.972% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -553.08% |
Evolus, Inc. | 209.68 Million USD | 73.556% |
HUTCHMED (China) Limited | 536.38 Million USD | 89.662% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 93.652% |
Akanda Corp. | 12.66 Million USD | -337.687% |